PFIZER INC.

Relay Therapeutics to report interim data for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer on Sept. 9, 2024, at 8am ET.

The Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028 report highlights the emergence of CD47 inhibition as a novel cancer immunotherapy, with multiple candidates in clinical trials, including magrolimab and evorpacept. The market is rapidly evolving, driven by rising cancer incidence and increased use of immunotherapies, with significant commercial interest and notable acquisitions. Challenges include managing toxicity and demonstrating therapeutic advantages over current treatments.

M.J.D. has consulted, advised, and spoken for Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, Pfizer, AstraZeneca, Zealand Pharma, Carmot/Roche, and Amgen. She has also received grants from AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Janssen, Sanofi-Aventis, and Eli Lilly. J.G. has no competing interests.

Worldwide Clinical Trials appoints Alessandra Vignola as president of cardiovascular and metabolic business unit, leveraging her 30+ years of experience in pharmaceutical and clinical research to drive advancements in diabetes, obesity, and cardiovascular-kidney-metabolic diseases.

Faruqi & Faruqi, LLP's James (Josh) Wilson encourages investors who suffered losses exceeding $100,000 in Moderna between January 18, 2023, and June 25, 2024, to contact him directly to discuss their options. The firm is investigating potential claims against Moderna and reminds investors of the October 8, 2024, deadline to seek the role of lead plaintiff in a federal securities class action. The complaint alleges Moderna and its executives violated federal securities laws by making false and/or misleading statements regarding mRNA-1345's efficacy.

A Phase II trial showed AstraZeneca's Lynparza (olaparib) effective in treating recurrent prostate cancer without hormone therapy, prompting larger follow-up studies in biomarker-selected subgroups. Lynparza, a PARP inhibitor, demonstrated efficacy in patients with homologous recombination repair gene mutations, particularly BRCA2, with higher response rates than seen with hormonal suppression. The study suggests that not all prostate cancer patients need hormone therapy and highlights the need for biomarker-selected trials to identify responders.

Upcoming webinars and presentations cover topics like the impact of Dobbs on reproductive health, clinical research glossary, health literacy, and data sharing. Publications include articles on clinical research workforce challenges, pediatric drug development during public health emergencies, and the role of institutional review boards in clinical research.

FDA approves new Pfizer and Moderna COVID-19 vaccines for fall, targeting KP.2 variant. Symptoms remain similar to previous variants, with high risk of complications. mRNA technology promotes immune response, differing from traditional vaccines. CDC recommends updated vaccine for all Americans six months and older. Limited vaccine supply available for uninsured and underinsured patients.

FDA approved updated COVID-19 vaccines targeting Omicron variants JN.1 and KP.2 for ages 12+, with mRNA vaccines by Moderna and Pfizer for ages 6 months+. CDC recommends vaccination for everyone 6 months+, emphasizing importance for high-risk groups. Timing and doses depend on vaccination status. JN.1, KP.2, KP.3, and KP.3.1.1 are circulating variants. Pharmacies like CVS and Kroger offer the vaccines.